Literature DB >> 20179793

Current concepts and future directions in differentiated thyroid cancer.

Donald S A McLeod1.   

Abstract

This paper provides an overview on the biology, monitoring and management of differentiated thyroid cancer (DTC), with particular attention to issues of relevance to clinical chemistry. The incidence of DTC appears to be increasing and management strategies are evolving as we learn more about its natural history and response to therapy. Clinical chemistry techniques play a central role in these protocols. Technical limitations inherent in current monitoring tools can hamper follow-up, although progress is being made. The molecular basis of DTC is being delineated with the potential to develop new strategies for diagnosis, monitoring and management of this condition.

Entities:  

Year:  2010        PMID： 20179793      PMCID： PMC2826267     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN： 0159-8090


  105 in total

1.  Genetic-targeted therapy of thyroid cancer: a real promise.

Authors:  Mingzhao Xing
Journal:  Thyroid       Date:  2009-08       Impact factor: 6.568

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer.

Authors:  F Pacini; L Fugazzola; F Lippi; C Ceccarelli; R Centoni; P Miccoli; R Elisei; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1992-06       Impact factor: 5.958

Review 4.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

5.  Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma.

Authors:  C A Spencer; M Takeuchi; M Kazarosyan; C C Wang; R B Guttler; P A Singer; S Fatemi; J S LoPresti; J T Nicoloff
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

6.  Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer.

Authors:  P Pujol; J P Daures; N Nsakala; L Baldet; J Bringer; C Jaffiol
Journal:  J Clin Endocrinol Metab       Date:  1996-12       Impact factor: 5.958

7.  Detection of circulating thyroid cells in peripheral blood.

Authors:  B A Ditkoff; M R Marvin; S Yemul; Y J Shi; J Chabot; C Feind; P L Lo Gerfo
Journal:  Surgery       Date:  1996-12       Impact factor: 3.982

8.  Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer.

Authors:  F Pacini; R Lari; S Mazzeo; L Grasso; D Taddei; A Pinchera
Journal:  Clin Endocrinol (Oxf)       Date:  1985-10       Impact factor: 3.478

9.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

10.  Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.

Authors:  D S Cooper; B Specker; M Ho; M Sperling; P W Ladenson; D S Ross; K B Ain; S T Bigos; J D Brierley; B R Haugen; I Klein; J Robbins; S I Sherman; T Taylor; H R Maxon
Journal:  Thyroid       Date:  1998-09       Impact factor: 6.568
View more
  8 in total

1.  Genetics of thyroid function and disease.

Authors:  Vijay Panicker
Journal:  Clin Biochem Rev       Date:  2011-11

2.  Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma.

Authors:  Yang Guang; Yukun Luo; Yan Zhang; Mingbo Zhang; Nan Li; Ying Zhang; Jie Tang
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-24       Impact factor: 4.553

3.  Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer.

Authors:  Yiling Guo; Yingnan Zhang; Zuowei Chen; Zhenfu Xin
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

4.  Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer.

Authors:  Tianyu Zhai; Dilidaer Muhanhali; Xi Jia; Zhiyong Wu; Zhenqin Cai; Yan Ling
Journal:  Endocrine       Date:  2019-07-22       Impact factor: 3.633

5.  Durable effect of radioactive iodine in a patient with metastatic follicular thyroid carcinoma.

Authors:  Aubrey A Carhill; Rena Vassilopoulou-Sellin
Journal:  Case Rep Endocrinol       Date:  2012-09-23

Review 6.  Cost-Effective Fiber Optic Solutions for Biosensing.

Authors:  Cátia Leitão; Sónia O Pereira; Carlos Marques; Nunzio Cennamo; Luigi Zeni; Madina Shaimerdenova; Takhmina Ayupova; Daniele Tosi
Journal:  Biosensors (Basel)       Date:  2022-07-28

7.  Value of Pyruvate Carboxylase in Thyroid Fine-Needle Aspiration Wash-Out Fluid for Predicting Papillary Thyroid Cancer Lymph Node Metastasis.

Authors:  Chang Liu; Lu Zhang; Yang Liu; Qingqing Zhao; Yu Pan; Yifan Zhang
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

8.  Design and validation of fiber optic localized surface plasmon resonance sensor for thyroglobulin immunoassay with high sensitivity and rapid detection.

Authors:  Hyeong-Min Kim; Dae Hong Jeong; Ho-Young Lee; Jae-Hyoung Park; Seung-Ki Lee
Journal:  Sci Rep       Date:  2021-08-06       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.